Indefinite Delivery Contract SPE2DB25D9767

The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) valued at up to $499,999,999, awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, under the SPE2DB program, aims to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to fulfill the recurring medical supply needs of military health facilities worldwide.

Specific products supplied under this IDC include flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications, as well as common medications like antibiotics, pain relievers, and cardiovascular drugs. The IDC covers the period from September 18, 2024, through November 30, 2026, and is primarily supported by firm fixed-price delivery orders placed by the DLA's Medical Supply Chain division for distribution to various Department of Defense (DoD) healthcare facilities globally. This contract complements DMS Pharmaceutical Group's existing prime vendor contracts for direct distribution of prescription drugs and pharmacy services to DoD sites, further solidifying the company's position as a crucial supplier in the federal pharmaceutical supply chain.